Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
// Min-Che Tung 1,3,* , Po-Lin Lin 4,* , Yao-Chen Wang 6 , Tsung-Ying He 4 , Ming-Ching Lee 7 , Sauh-Der Yeh 1 , Chih-Yi Chen 5 and Huei Lee 2 1 Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan 2 Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan 3 Department of Surgery, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan 4 Institute of Medicine, Department of Surgery, Chung Shan Medical University, Taichung, Taiwan 5 Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University, Taichung, Taiwan 6 Division of Chest Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan 7 Department of Thoracic Surgery, Taichung Veteran General Hospital, Taichung, Taiwan * These authors contributed equally to this work Correspondence to: Huei Lee, email: // Keywords : Nrf2, p53, cisplatin sensitivity, lung cancer Received : July 20, 2015 Accepted : September 30, 2015 Published : October 19, 2015 Abstract Nrf2 is a key transcription factor for genes coding for antioxidants, detoxification enzymes, and multiple drug resistance and it also confers resistance to anticancer drugs. Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Luciferase reporter assays and real-time PCR analysis indicated that the Nrf2 promoter activity and its mRNA levels were markedly suppressed by wild-type p53, but not by mutant p53. Chromatin immunoprecipitation (ChIP) further confirmed that wild-type p53 binds at the p53 putative binding site to block Sp1 binding to the Nrf2 promoter and consequently to suppress the Nrf2 promoter activity. The MTT assay indicated that an increase in Nrf2 expression by mutant p53 is responsible for cisplatin resistance. Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. The prognostic significance of Nrf2 mRNA levels on OS and RFS was also observed in patients who have received cisplatin-based chemotherapy, particularly in p53-mutant patients. Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 2×
“ROS levels are tightly controlled by the Nrf2/Keap1 pathway [38].”
BackgroundThe Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313 · cited 1×
“Gene expression of antioxidants that eliminate ROS is promoted by an NF-E2related factor 2 (Nrf2), which binds to antioxidant response elements (ARE) of the promoters of these genes [7-11].”
BackgroundDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 6×
“Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.”
BackgroundInfluentialSelf-citationMarullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081162 · Cited by 777 · cited 8×
“Gene expression of antioxidants that eliminate ROS is promoted by an NF-E2related factor 2 (Nrf2), which binds to antioxidant response elements (ARE) of the promoters of these genes [7-11].”
InfluentialStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 6×
“Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.”
BackgroundInfluentialDirect Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638 · cited 1×
“For example, binding of the p53 downstream p21 to Nrf2 inhibits Nrf2 degradation [26], whereas binding of the Nrf2 downstream NAD(P) H dehydrogenase quinone 1 (NQO1) to p53 prevents p53 degradation [27].”
BackgroundNQO1 stabilizes p53 through a distinct pathway
Asher, G., Lotem, J., Kama, R., Sachs, L., & Shaul, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706799 · Cited by 291 · cited 1×
“For example, binding of the p53 downstream p21 to Nrf2 inhibits Nrf2 degradation [26], whereas binding of the Nrf2 downstream NAD(P) H dehydrogenase quinone 1 (NQO1) to p53 prevents p53 degradation [27].”
BackgroundOncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291
Rushworth, S. A., Zaitseva, L., Murray, M. Y., Shah, N. M., Bowles, K. M., & MacEwan, D. J. (2012) · Blood · doi:10.1182/blood-2012-04-422121 · Cited by 290
Cited by
NRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“The mutated form of the tumor suppressor p53, which sustains the growth of cancer cells by enhancing nutrient uptake and synthesis of building blocks, can also upregulate NRF2, possibly through the crosstalk with the Sp1 transcription factor that binds to the NRF2 promoter (Tung et al., 2015).”
BackgroundThe role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
Canonical and non-canonical mechanisms of Nrf2 activation
Silva-Islas, C. A., & Maldonado, P. D. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.013 · Cited by 388
The Role of Nrf2 Activity in Cancer Development and Progression
Zimta, A.-A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan-Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11111755 · Cited by 292
Role of Nrf2 and Its Activators in Respiratory Diseases
Liu, Q., Gao, Y., & Ci, X. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7090534 · Cited by 267
Involvement of Nrf2 in myocardial ischemia and reperfusion injury
Shen, Y., Liu, X., Shi, J., & Wu, X. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.190 · Cited by 261
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Antioxidants: Positive or Negative Actors?
Salehi, B., Martorell, M., Arbiser, J., Sureda, A., Martins, N., Maurya, P., Sharifi-Rad, M., Kumar, P., & Sharifi-Rad, J. (2018) · Biomolecules · doi:10.3390/biom8040124 · Cited by 255
p53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123
Metadata
- Authors
- Tung, M.-C., Lin, P.-L., Wang, Y.-C., He, T.-Y., Lee, M.-C., Yeh, S.-D., Chen, C.-Y., & Lee, H.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-19
- Volume
- 6
- Issue
- 39
- Pages
- 41692-41705
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1859299832
- Cited by
- 138
- References
- 11
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.